Aquestive Therapeutics reports Q1 2024 results, FDA approval of Libervant, and progress on Anaphylm

Aquestive Therapeutics, Inc.

2024-Q1 EPS reported -$0.17 revenue$12,053,000

Met all endpoints in Phase 3 pivotal study for Anaphylm (epinephrine) Sublingual Film compared to EpiPen and other injectors.
Received FDA approval for Libervant (diazepam) Buccal Film in patients ages 2-5, now available in multiple strengths.
Completed $77.5M underwritten public offering with institutional investors, extending cash runway into 2026.
Total revenues increased to $12.1M in Q1 2024 from $11.1M in Q1 2023; net loss was $12.8M.
On track to file Anaphylm NDA with FDA by end of 2024, with remaining studies expected by Q3 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Aquestive Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the first quarter ended March 31, 2024 and provided an update on recent developments in its business.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-021110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.